Sotiris Mastoridis

Sotiris Mastoridis

Auto-generated profile, based on publicly available information

Sotiris Mastoridis

Oxford Oesophagogastric Centre, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 June 2020 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
SMSotiris Mastoridis
Sotiris Mastoridis
MLMaría-Carlota Londoño
María-Carlota Londoño
AKAda Kurt
Ada Kurt
EKElisavet Kodela
Elisavet Kodela
ECElena Crespo
Elena Crespo
ASAlberto Sánchez-Fueyo
Alberto Sánchez-Fueyo
In several murine models of transplantation, the ‘cross‐dressing’ of recipient antigen presenting cells (APCs) with intact donor major histocompatibility complex (MHC) derived from allograft‐released small extracellular vesicles (sEVs) has been recently described as a key mechanism in eliciting and sustaining alloimmune responses. Investigation of these processes in clinical organ transplantation has however been hampered by the lack of sensitivity of conventional instruments and assays. We have employed Advanced Imaging Flow Cytometry (iFCM) to explore the kinetics of allograft sEV release and the extent to which donor sEVs might induce cross‐dressing following liver and kidney transplantation. We report for the first time that recipient APC cross‐dressing can be transiently detected in the circulation shortly after liver, but not kidney, transplantation in association with the release of HLA‐bearing allograft‐derived sEVs. In liver transplant recipients the majority of circulating cells exhibiting donor HLA are indeed cross‐dressed cells and not passenger leukocytes. In keeping with experimental animal data, the downstream functional consequences of the transfer of circulating sEVs harvested from human transplant recipients varies depending on the type of transplant and time post‐transplantion. sEVs released shortly after liver, but not kidney, transplantation exhibit immunoinhibitory effects that could influence liver allograft immunogenicity.

30 November 2021 in Clinical Endoscopy
Verified
Journal Article
Open access
PDF file
ILImogen Livingstone
Imogen Livingstone
LPLily Pollock
Lily Pollock
BSBruno Sgromo
Bruno Sgromo
SMSotiris Mastoridis
Sotiris Mastoridis
Esophageal wall defects, including perforations and postoperative leaks, are associated with high morbidity and mortality and pose a significant management challenge. In light of the high morbidity of surgical management or revision, in recent years, endoscopic vacuum therapy (EVT) has emerged as a novel alternative treatment strategy. EVT involves transoral endoscopic placement of a polyurethane sponge connected to an externalized nasogastric tube to provide continuous negative pressure with the intention of promoting defect healing, facilitating cavity drainage, and ameliorating sepsis. In the last decade, EVT has become increasingly adopted in the management of a diverse spectrum of esophageal defects. Its popularity has been attributed in part to the growing body of evidence suggesting superior outcomes and defect closure rates in excess of 80%. This growing body of evidence, coupled with the ongoing evolution of the technology and techniques of deployment, suggests that the utilization of EVT has become increasingly widespread. Here, we aimed to review the current status of the field, addressing the mechanism of action, indications, technique methodology, efficacy, safety, and practical considerations of EVT implementation. We also sought to highlight future directions for the use of EVT in esophageal wall defects.

10 August 2020 in Minimally Invasive Therapy & Allied Technologies
Verified
Journal Article
Closed access
SMSotiris Mastoridis
Sotiris Mastoridis
PCPrem Chana
Prem Chana
MSMohan Singh
Mohan Singh
KAKhalid Akbari
Khalid Akbari
SSSamar Shalaby
Samar Shalaby
BSBruno Sgromo
Bruno Sgromo
Oesophageal perforations and post-oesophagectomy anastomotic leaks are associated with high morbidity and mortality. Endoscopic vacuum therapy (EVT) is a novel treatment strategy with the potential...

1 February 2015 in Current Opinion in Organ Transplantation
Verified
Journal Article
Closed access
SMSotiris Mastoridis
Sotiris Mastoridis
Fadi IssaFadi Issa
Fadi Issa
KWKathryn J. Wood
Kathryn J. Wood
Cell-based immunotherapy offers a novel approach to minimize the need for immunosuppressive drugs and to promote a state of immunological tolerance to a transplanted organ. We review the most promising biomarkers and functional assays able to identify patients tolerant to their graft. Such a signature of tolerance is essential in the assessment of the efficacy with which trials of cellular therapies promote immunoregulation and minimize graft rejection. A multitude of novel cellular therapies have entered early-phase clinical trials in solid-organ transplant patients. Recent multicentre collaborations have enabled the determination of distinct tolerance profiles for both liver and kidney transplant recipients. These have been shown to be highly predictive of tolerance in certain settings and show utility in identifying patients in whom immunosuppressive drugs can be weaned or discontinued. In order to become a viable treatment option in solid-organ transplantation, the latest large, multicentre clinical trials of cellular therapies must utilize, validate and discover the biomarkers with the capacity to reliably identify a signature of immune tolerance.

30 September 2022 in The Surgeon
Verified
Journal Article
Closed access
SBSaumya Bhagat
Saumya Bhagat
JEJihene El-Kafsi
Jihene El-Kafsi
KSKumarakrishnan Samraj
Kumarakrishnan Samraj
SMSotiris Mastoridis
Sotiris Mastoridis

18 January 2021 in Research Square
Verified
Preprint
Open access
PDF file
SMSotiris Mastoridis
Sotiris Mastoridis
GBGiada Bracalente
Giada Bracalente
CHChistine-Bianca Hanganu
Chistine-Bianca Hanganu
MNMichela Neccia
Michela Neccia
AGAntonio Giuliani
Antonio Giuliani
BSBruno Sgromo
Bruno Sgromo
Background: Jejunal feeding is an invaluable method by which to improve the nutritional status of patients undergoing neoadjuvant and surgical treatment of oesophageal malignancies. However, the insertion of a feeding jejunostomy can cause significant postoperative morbidity. The aim of this study is to compare the outcomes of patients undergoing placement of feeding jejunostomy by conventional laparotomy with an alternative laparoscopic approach. Methods: A retrospective review of data prospectively collected at the Oxford Oesophagogastric Centre between August 2017 and July 2019 was performed including consecutive patients undergoing feeding jejunostomy insertion. Results: In the study period, 157 patients underwent jejunostomy insertion in the context of oesophageal cancer therapy, 126 (80%) by open technique and 31 (20%) laparoscopic. Pre-operative demographic and nutritional characteristics were broadly similar between groups. In the early postoperative period jejunostomy-associated complications were noted in 54 cases (34.4%) and were significantly more common among those undergoing open as compared with laparoscopic insertion (38.1% vs 19.3%, P = 0.049). Furthermore, major complications were more common among those undergoing open insertion, whether as a stand-alone or at the time of staging laparoscopy (n = 11/71), as compared with insertion at the time of oesophagectomy (n = 3/86, P = 0.011). Conclusions: This report represents the largest to our knowledge single-centre comparison of open versus laparoscopic jejunostomy insertion in patients undergoing oesophagectomy in the treatment of gastroesophageal malignancy. We conclude that the laparoscopic jejunostomy insertion technique described represents a safe and effective approach to enteral access which may offer superior outcomes to conventional open procedures.